The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)
Published in 2016 by
Michael Roost Clausen,
Sirpa Marianne Leppä 
,
Peter de Nully Brown,
Jette Soenderskov Goerloev,
Michael Panny,
Wolfgang Willenbacher,
Ida Blok Sillesen,
Erik Segel,
Hans Bentzen,
Michael Thorsgaard,
Elisa Jacobsen Pulczynski,
Peter Kamper,
Lars C. Gormsen,
Julie Mortensen,
Grethe Lauritzsen
and other authors.
,
Peter de Nully Brown,
Jette Soenderskov Goerloev,
Michael Panny,
Wolfgang Willenbacher,
Ida Blok Sillesen,
Erik Segel,
Hans Bentzen,
Michael Thorsgaard,
Elisa Jacobsen Pulczynski,
Peter Kamper,
Lars C. Gormsen,
Julie Mortensen,
Grethe Lauritzsen
and other authors.
